CN Bio Innovations (CN Bio) today announced the appointment of Professor Mark Thursz as a scientific advisor to the company.
“Mark has considerable experience and a deep knowledge of clinical hepatology and related non-clinical research and I believe that CN Bio will benefit from having access to Mark’s expertise as we continue to develop and bring to market our novel and proprietary liver disease models” said David Scales, CEO of CN Bio.
Professor Thursz is Professor of Hepatology at Imperial College London where he is Head of the Section of Hepatology and Gastroenterology, and consultant in hepatology at St Mary’s Hospital, London. Professor Thursz’ research interests are focussed on the natural history of viral hepatitis and fatty liver disease and the factors which determine chronic infection and progressive liver disease. Professor Thursz is a former Secretary General of the European Association for Study of the Liver (EASL).